Drugs that contain Nusinersen Sodium

1. Drug name - SPINRAZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7101993 BIOGEN IDEC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(11 months from now)

US7838657 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Jul, 2027

(4 years from now)

US8361977 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing
May, 2030

(7 years from now)

EP604409B1 BIOGEN IDEC Oligonucleotide Analogs For Detecting And Modulating Rna Activity And Gene Expression
Jan, 2011

(11 years ago)

EP604409A4 BIOGEN IDEC Compositions And Methods For Detecting And Modulating Rna Activity And Gene Expression.
Jan, 2011

(11 years ago)

EP604409A1 BIOGEN IDEC Oligonucleotide Analogs For Detecting And Modulating Rna Activity And Gene Expression
Jan, 2011

(11 years ago)

EP517859A1 BIOGEN IDEC Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP517859A4 BIOGEN IDEC Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP517859B1 BIOGEN IDEC Oligonucleotide Therapies For Modulating The Effects Of Herpesviruses
Feb, 2011

(11 years ago)

EP529008B1 BIOGEN IDEC Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP529008A4 BIOGEN IDEC Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP529008A1 BIOGEN IDEC Modulation Of Gene Expression Through Interference With Rna Secondary Structure
Apr, 2011

(11 years ago)

EP544757A4 BIOGEN IDEC Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544757A1 BIOGEN IDEC Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544757B1 BIOGEN IDEC Novel Polyamine Conjugated Oligonucleotides
Jun, 2011

(11 years ago)

EP544716A4 BIOGEN IDEC Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP544716A1 BIOGEN IDEC Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP544716B1 BIOGEN IDEC Oligonucleotide Modulation Of Cell Adhesion
Jul, 2011

(11 years ago)

EP549615A4 BIOGEN IDEC Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP549615B1 BIOGEN IDEC Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP544792A1 BIOGEN IDEC Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP544792B1 BIOGEN IDEC Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP544792A4 BIOGEN IDEC Novel Nucleoside Analogs
Aug, 2011

(11 years ago)

EP549615A1 BIOGEN IDEC Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression
Aug, 2011

(11 years ago)

EP544713A1 BIOGEN IDEC Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP544713B1 BIOGEN IDEC Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP544713A4 BIOGEN IDEC Oligonucleotides For Modulating The Effects Of Cytomegalovirus Infections
Aug, 2011

(11 years ago)

EP586570A4 BIOGEN IDEC Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP586570B1 BIOGEN IDEC Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP586520B1 BIOGEN IDEC Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP586520A4 BIOGEN IDEC Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP586570A1 BIOGEN IDEC Backbone Modified Oligonucleotide Analogues
May, 2012

(10 years ago)

EP586520A1 BIOGEN IDEC Backbone Modified Oligonucleotide Analogs
May, 2012

(10 years ago)

EP590082A4 BIOGEN IDEC Antisense Oligonucleotide Inhibition Of The Ras Gene.
Jun, 2012

(10 years ago)

EP590082A1 BIOGEN IDEC Antisense Oligonucleotide Inhibition Of The Ras Gene
Jun, 2012

(10 years ago)

EP590082B1 BIOGEN IDEC Antisense Oligonucleotide Inhibition Of The Ras Gene
Jun, 2012

(10 years ago)

EP655088A4 BIOGEN IDEC Oligonucleotides Having Chiral Phosphorus Linkages.
Oct, 2012

(9 years ago)

EP655088A1 BIOGEN IDEC Oligonucleotides Having Chiral Phosphorus Linkages
Oct, 2012

(9 years ago)

EP655088B1 BIOGEN IDEC Oligonucleotides Having Chiral Phosphorus Linkages
Oct, 2012

(9 years ago)

EP724447B1 BIOGEN IDEC Derivatized Oligonucleotides Having Improved Uptake
Oct, 2012

(9 years ago)

EP724447A4 BIOGEN IDEC Derivatized Oligonucleotides Having Improved Uptake And Other Properties
Oct, 2012

(9 years ago)

EP724447A1 BIOGEN IDEC Derivatized Oligonucleotides Having Improved Uptake
Oct, 2012

(9 years ago)

EP1695979A3 BIOGEN IDEC Gapped 2' Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1695979A2 BIOGEN IDEC Gapped Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1695979B1 BIOGEN IDEC Gapped Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP618925B1 BIOGEN IDEC Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP618925A1 BIOGEN IDEC Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987A2 BIOGEN IDEC Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987A3 BIOGEN IDEC Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP1044987B1 BIOGEN IDEC Gapped 2'-Modified Oligonucleotides
Dec, 2012

(9 years ago)

EP618925A4 BIOGEN IDEC Gapped 2' Modified Oligonucleotides.
Dec, 2012

(9 years ago)

EP618925B2 BIOGEN IDEC Antisense Oligonucleotides
Dec, 2012

(9 years ago)

EP672180B1 BIOGEN IDEC Oligonucleotide Modulation Of Protein Kinase C
Feb, 2013

(9 years ago)

EP672180A4 BIOGEN IDEC Oligonucleotide Modulation Of Protein Kinase C.
Feb, 2013

(9 years ago)

EP672180A1 BIOGEN IDEC Oligonucleotide Modulation Of Protein Kinase C
Feb, 2013

(9 years ago)

EP649429A1 BIOGEN IDEC Heteroatomic Oligonucleoside Linkages
May, 2013

(9 years ago)

EP649429B1 BIOGEN IDEC Heteroatomic Oligonucleoside Linkages
May, 2013

(9 years ago)

EP649429A4 BIOGEN IDEC Heteroatomic Oligonucleoside Linkages.
May, 2013

(9 years ago)

EP1223173B1 BIOGEN IDEC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP651759B1 BIOGEN IDEC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP1223173A2 BIOGEN IDEC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP1223173A3 BIOGEN IDEC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP651759A4 BIOGEN IDEC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof.
Jul, 2013

(9 years ago)

EP651759A1 BIOGEN IDEC Novel 2'-O-Alkyl Nucleosides And Phosphoramidites Processes For The Preparation And Uses Thereof
Jul, 2013

(9 years ago)

EP662003A4 BIOGEN IDEC Oligonucleotide Modulation Of Cell Adhesion.
Aug, 2013

(9 years ago)

EP662003A1 BIOGEN IDEC Oligonucleotide Modulation Of Cell Adhesion
Aug, 2013

(9 years ago)

EP662003B1 BIOGEN IDEC Oligonucleotide Modulation Of Cell Adhesion
Aug, 2013

(9 years ago)

EP672193B1 BIOGEN IDEC Use Of Oligonucleotides Having A Conserved G 4 Core Sequence For The Preparation Of A Medicament
Sep, 2013

(9 years ago)

EP672193A1 BIOGEN IDEC Use Of Oligonucleotides Having A Conserved G 4 Core Sequence For The Preparation Of A Medicament
Sep, 2013

(9 years ago)

EP672193A4 BIOGEN IDEC Oligonucleotides Having A Conserved G 4? Core Sequence.
Sep, 2013

(9 years ago)

EP716604A4 BIOGEN IDEC Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP716604B1 BIOGEN IDEC Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP716604A1 BIOGEN IDEC Thiol-Derivatized Nucleosides And Oligonucleosides
Aug, 2014

(8 years ago)

EP728139A4 BIOGEN IDEC Gapped Oligonucleotides
Sep, 2014

(8 years ago)

EP728139B1 BIOGEN IDEC Amine-Derivatized Nucleosides And Oligonucleosides
Sep, 2014

(8 years ago)

EP728139A1 BIOGEN IDEC Amine-Derivatized Nucleosides And Oligonucleosides
Sep, 2014

(8 years ago)

EP734391B1 BIOGEN IDEC Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP734391A1 BIOGEN IDEC Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP734391A4 BIOGEN IDEC Pna-Dna-Pna Chimeric Macromolecules
Nov, 2014

(7 years ago)

EP731807B1 BIOGEN IDEC N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP731807A4 BIOGEN IDEC N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP731807A1 BIOGEN IDEC N-2 Substituted Purines
Nov, 2014

(7 years ago)

EP881914A1 BIOGEN IDEC Methoxyethoxy Oligonucleotides For Modulation Of Protein Kinase C Expression
Feb, 2017

(5 years ago)

EP881914A4 BIOGEN IDEC Gapped Oligonucleotides
Feb, 2017

(5 years ago)

EP881914B1 BIOGEN IDEC Methoxyethoxy Oligonucleotides For Modulation Of Protein Kinase C Expression
Feb, 2017

(5 years ago)

EP1218395A4 BIOGEN IDEC Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1218395B1 BIOGEN IDEC Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1218395A1 BIOGEN IDEC Antisense Modulation Of X-Linked Inhibitor Of Apoptosis Expression
Jan, 2020

(2 years ago)

EP1325019A4 BIOGEN IDEC Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 16 days ago)

EP1325019A1 BIOGEN IDEC Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 16 days ago)

EP1325019B1 BIOGEN IDEC Antisense Modulation Of Clusterin Expression
Sep, 2021

(1 year, 16 days ago)

EP3308788B1 BIOGEN IDEC Compositions And Methods For Modulation Of Smn2 Splicing
Jun, 2026

(3 years from now)

EP3308788A1 BIOGEN IDEC Compositions And Methods For Modulation Of Smn2 Splicing
Jun, 2026

(3 years from now)

EP1910395A2 BIOGEN IDEC Compositions And Methods For Modulation Of Smn2 Splicing
Jun, 2026

(3 years from now)

EP2548560B1 BIOGEN IDEC Compositions And Methods For Modulation Of Smn2 Splicing
Jun, 2026

(3 years from now)

EP1910395A4 BIOGEN IDEC Compositions And Methods For Modulation Of Smn2 Splicing
Jun, 2026

(3 years from now)

EP1910395B1 BIOGEN IDEC Compositions And Methods For Modulation Of Smn2 Splicing
Jun, 2026

(3 years from now)

EP2548560A1 BIOGEN IDEC Compositions And Methods For Modulation Of Smn2 Splicing
Jun, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266822 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Dec, 2025

(3 years from now)

US8110560 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Dec, 2025

(3 years from now)

US9717750 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject Jun, 2030

(7 years from now)

US8980853 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject Nov, 2030

(8 years from now)

US9926559 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject Jan, 2034

(11 years from now)

US10436802 BIOGEN IDEC Methods for treating spinal muscular atrophy Sep, 2035

(12 years from now)

Treatment: Treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; treatment of spinal muscular atrophy; Treatment of spinal muscular atrophy; treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; treatment of type iii spinal muscular atrophy; treatment of type ii spinal muscular atrophy; treatment of spinal muscular atrophy; Treatment of infantile-onset spinal muscular atrophy; Treatment of spinal muscular atrophy; Treatment of type iii spinal muscular atrophy; treatment of spinal muscular atrophy; treatment of infantile-onset spinal muscular atrophy; treatment of type ii spinal muscular atrophy; treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage
Strength Dosage Availability
EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) SOLUTION;INTRATHECAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.